Sexually Transmitted Disease Diagnostics Market by Product Types (Consumables, Instruments, Reagents and Kits), Diagnostic Test Types (Laboratory Tests, Molecular Tests, Point-of-Care Tests), Pathogen Types, Sample Types, Technology Types, End-User Types
Description
The Sexually Transmitted Disease Diagnostics Market was valued at USD 112.56 billion in 2024 and is projected to grow to USD 119.42 billion in 2025, with a CAGR of 6.19%, reaching USD 182.11 billion by 2032.
A focused strategic introduction that frames diagnostic innovations, health system priorities, and procurement imperatives shaping sexually transmitted infection testing decisions
This executive summary introduces a focused analysis of sexually transmitted infection diagnostics, concentrating on the intersection of technological innovation, shifting epidemiology, and evolving health-system priorities. Diagnostic leaders, clinical directors, policymakers, and commercial strategists will find an evidence-based narrative that situates recent advances in molecular and rapid testing within real-world constraints such as reimbursement, supply chain resiliency, and patient access. The introduction frames current dialogues around diagnostic accuracy, time-to-result, and decentralization, emphasizing how these factors shape adoption curves across public health programs and clinical pathways.
The narrative begins with a clear description of diagnostic modalities, followed by an exploration of demand-side drivers including testing guidelines, screening initiatives, and changing sexual health behaviors. It then transitions to the supply-side context, describing manufacturing capacity, regulatory alignment, and cross-border trade dynamics that influence product availability. The section closes by articulating the principal decision imperatives for stakeholders: optimizing diagnostic portfolios for sensitivity and scalability, designing service models that expand reach without compromising quality, and prioritizing investments that reduce time-to-diagnosis while maintaining cost-effectiveness.
How converging technological breakthroughs, regulatory evolution, and care-delivery redesign are reshaping diagnostic pathways and adoption dynamics across sexual health services
The diagnostics landscape is undergoing transformative shifts driven by scientific breakthroughs, regulatory evolution, and care-delivery redesign. Advances in nucleic acid amplification and next-generation sequencing have redefined sensitivity thresholds and enabled multiplexed pathogen detection, while CRISPR-based platforms and microfluidic lab-on-a-chip systems are opening pathways for high-performance decentralised testing. These technological shifts are complemented by the maturation of point-of-care formats, where rapid diagnostic tests and compact analyzers are increasingly viable for community screening and home-based testing models.
Concurrently, regulatory frameworks are adapting to balance expedited access with robust validation, leading to new pathways for emergency authorization and conditional approvals in certain jurisdictions. Health systems are also realigning around patient-centric care, prioritizing same-visit diagnosis and linkage to treatment to reduce transmission risk. The convergence of improved digital connectivity, telehealth, and remote sample collection is reshaping how tests are ordered, fulfilled, and integrated into care pathways, which in turn drives demand for interoperable data standards and secure reporting mechanisms. Taken together, these shifts create both opportunity and risk: innovators that align product performance with real-world workflow and reimbursement constraints will scale more rapidly, while fragmented approaches that ignore implementation realities will face adoption hurdles.
Assessing how recent tariff pressures are redirecting supply chains, elevating input costs, and prompting localization and partnership strategies across diagnostic value chains
The imposition and escalation of tariffs can materially affect the diagnostic ecosystem by altering input costs, redirecting supply chains, and influencing sourcing strategies. For manufacturers of instruments, consumables, and reagents, higher import tariffs increase landed costs for components such as reagent raw materials, plastics for consumables, and precision components used in analyzers. These cost pressures incentivize manufacturers to re-evaluate sourcing footprints, pursue near-shoring, or consolidate supplier relationships to preserve margins and maintain predictable supply.
From a distribution and end-user perspective, tariff-induced cost increases can cascade into higher per-test prices, influencing procurement decisions by hospitals, public health departments, and large laboratories. Buyers may respond by shifting volume to lower-cost suppliers, extending inventory horizons, or prioritizing multi-use instruments that reduce reliance on imported single-use consumables. Tariffs also accelerate strategic partnerships, contract manufacturing arrangements, and cross-border investment as firms seek to mitigate exposure to trade policy volatility. Finally, increased trade friction tends to heighten emphasis on regulatory harmonization and bilateral agreements that can restore market access and stabilize supply. In sum, tariffs in 2025 reshape commercial calculus, driving localization, supplier rationalization, and renewed focus on margin resilience without reducing the imperative for testing quality and timely access.
A nuanced segmentation framework connecting diagnostic modalities, pathogen biology, end-user settings, sampling protocols, technologies, and product forms to strategic decision-making
Insightful segmentation reveals how diagnostic strategies must be tailored to product capability, pathogen biology, end-user setting, sample modality, technology platform, and product form. Diagnostic test types span laboratory tests that include biomarker-based assays, blood tests, and urine tests; molecular tests that encompass next-generation sequencing, nucleic acid amplification tests, and polymerase chain reaction; and point-of-care tests that feature portable analyzers, rapid diagnostic tests, and self-test kits. Each test category presents distinct trade-offs between throughput, sensitivity, and decentralization, and clinical programs must align modality selection with screening intensity and linkage-to-care capacity.
Pathogen-focused segmentation highlights that bacterial STDs such as Chlamydia, Gonorrhea, and Syphilis require different diagnostic chemistries and sampling strategies compared with fungal infections like candidiasis, parasitic pathogens such as Trichomoniasis, or viral agents including Hepatitis B, Herpes Simplex Virus, HIV, and HPV. End-user segmentation underscores divergent operational realities: diagnostic laboratories, which include both pathology and research labs, operate at scale and favor high-throughput platforms; home care settings, encompassing direct-to-consumer testing and online pharmacies, prioritize ease-of-use and privacy; hospitals and clinics, from large healthcare facilities to outpatient clinics, require rapid, reliable results integrated into clinical workflows; and public health departments, including community health centers and state health departments, emphasize standardization, surveillance compatibility, and cost-effectiveness.
Sample-type distinctions-blood samples subdivided into plasma and serum, swab samples covering genital, oral, and rectal swabs, and urine samples differentiated by first-catch and midstream-drive collection protocols, patient instructions, and downstream assay validation. Technology-type segmentation highlights emergent platforms such as CRISPR-based diagnostics, immunoassays including ELISA and lateral flow formats, microfluidic lab-on-a-chip solutions, and spectroscopy approaches like infrared and Raman, each offering different performance envelopes and integration demands. Finally, product segmentation into consumables such as pipettes and tubes, instruments like analyzers and automation systems, and reagents and kits for bacterial and viral pathogens underscores commercial planning considerations: procurement cycles, recurring spend profiles, and opportunities for bundled service models. Integrating these segmentation axes enables more nuanced targeting, product development prioritization, and go-to-market strategies that reflect both clinical needs and operational realities.
How divergent regional priorities and infrastructure realities across the Americas, Europe, Middle East & Africa, and Asia-Pacific determine adoption pathways and commercialization strategies
Regional dynamics exert a powerful influence on diagnostic adoption and innovation pathways, and leaders should consider geographic differentiation when designing market entry and distribution plans. In the Americas, investment in public health infrastructure, expansive private laboratory networks, and progressive reimbursement policies support rapid uptake of molecular testing and decentralized point-of-care solutions, while persistent disparities in access and rural health delivery create targeted opportunities for portable and self-testing formats. Europe, Middle East & Africa presents a heterogeneous picture: Western Europe exhibits mature regulatory alignment and strong laboratory capacity that favor high-complexity assays, whereas parts of the Middle East and Africa face infrastructure limitations that elevate the importance of ruggedized rapid tests, simplified workflows, and capacity-building partnerships.
Asia-Pacific is characterized by rapid technological adoption, significant domestic manufacturing capabilities, and diverse market maturities; advanced economies in the region often drive early uptake of cutting-edge platforms such as CRISPR-based diagnostics and lab automation, while emerging markets prioritize affordability, supply chain resilience, and scalable point-of-care testing. Across all regions, cross-border regulatory pathways, local validation requirements, and procurement modalities such as centralized tenders or decentralized hospital purchasing shape commercialization timelines. Effective regional strategies therefore combine local regulatory intelligence, partnership models that address distribution and training needs, and product portfolios calibrated to the operational realities of each geography.
Competitive landscape analysis emphasizing platform modularity, strategic partnerships, and evidence-driven differentiation as determinants of commercial success in diagnostics
Competitive dynamics are driven by incumbents that command established channel relationships and newer entrants that leverage platform innovations to target unmet clinical needs. Leading instrument and reagent providers continue to invest in modular platforms that enable multiplex testing and automated workflows, while agile startups focus on disruptive point-of-care formats, CRISPR-based approaches, and integrated digital reporting. Strategic differentiation increasingly rests on system-level value propositions: ease of integration with laboratory information systems, demonstrable improvements in time-to-result linked to treatment initiation, and robust post-market performance data that supports payer and public-health adoption.
Partnerships between diagnostics companies and contract manufacturers or local distributors are accelerating market access, especially where regulatory landscapes require domestic representation or local validation. In addition, collaborations with digital health companies and telemedicine platforms are creating new pathways for test ordering, result delivery, and care navigation, broadening addressable use cases beyond traditional clinical settings. Firms that balance continuous product innovation with scalable manufacturing and clear evidence-generation plans will be best positioned to capture institutional procurement and public health contracts, while those that over-index on novelty without clear implementation strategies risk slow adoption.
Practical and prioritized recommendations for executives to align innovation, supply resilience, evidence generation, and partnerships that accelerate adoption
Industry leaders should prioritize a set of pragmatic actions that balance innovation with implementation to accelerate impact and commercial traction. First, align product development with validated clinical workflows by engaging early with healthcare providers and public-health stakeholders to ensure assays address real-world sample types, throughput needs, and reporting requirements. Second, build resilient supply chains through supplier diversification, regional manufacturing partnerships, and inventory strategies that mitigate tariff and trade volatility while protecting quality standards.
Third, invest in evidence generation that demonstrates improved patient outcomes, linkage to care, and cost-effectiveness under routine conditions, thus facilitating payer engagement and public-health procurement. Fourth, pursue strategic commercial partnerships for distribution, training, and after-sales support to reduce barriers to adoption in resource-limited settings. Fifth, design digital interoperability into products from the outset to enable seamless data exchange with electronic health records and surveillance systems. Taken together, these recommendations create a pragmatic roadmap that balances near-term access goals with longer-term innovation and scale.
A transparent research methodology integrating primary stakeholder interviews, secondary literature synthesis, and rigorous validation to ensure practical and actionable insights
The research methodology combines structured primary outreach, rigorous secondary-source synthesis, and cross-validation of technical performance claims to ensure analytical robustness. Primary inputs included structured interviews with clinical laboratory directors, public-health officials, procurement officers, and R&D leaders, along with anonymized input from device engineers and assay developers to capture implementation constraints and performance expectations. Secondary research synthesized peer-reviewed literature, regulatory guidance documents, technology validation studies, and public health surveillance reports to contextualize clinical needs and technological capabilities.
Analytical methods used a matrixed approach to map technology attributes against clinical and operational requirements, and included scenario analysis to consider supply-chain disruptions and policy shifts. Validation steps included triangulation across multiple stakeholder types and review of real-world implementation case studies to ensure the findings reflect practical constraints. Where appropriate, technical claims and performance metrics were reviewed against published validation studies and regulatory summaries to maintain factual accuracy and applicability for decision-making audiences.
A definitive synthesis that links technological innovation, implementation realities, and strategic imperatives to drive measurable impact across diagnostic and public health objectives
In conclusion, the diagnostics sector for sexually transmitted infections is at an inflection point where scientific advances, evolving care models, and shifting trade dynamics converge to redefine how testing is delivered and scaled. The most successful strategies will integrate high-performance assays with pragmatic deployment plans that reflect the realities of sample collection, laboratory capacity, and payer expectations. Continued innovation will be necessary to close persistent gaps in access, particularly for underserved populations and decentralized settings where point-of-care and self-test modalities can have outsized impact.
Stakeholders must prioritize evidence generation that links diagnostic performance to patient outcomes, invest in resilient supply chains and regional partnerships to mitigate policy-driven risk, and design products with interoperability and usability at their core. By combining technological rigor with implementation-focused commercialization, organizations can translate diagnostic innovation into measurable public-health benefit and sustainable commercial value.
Note: PDF & Excel + Online Access - 1 Year
A focused strategic introduction that frames diagnostic innovations, health system priorities, and procurement imperatives shaping sexually transmitted infection testing decisions
This executive summary introduces a focused analysis of sexually transmitted infection diagnostics, concentrating on the intersection of technological innovation, shifting epidemiology, and evolving health-system priorities. Diagnostic leaders, clinical directors, policymakers, and commercial strategists will find an evidence-based narrative that situates recent advances in molecular and rapid testing within real-world constraints such as reimbursement, supply chain resiliency, and patient access. The introduction frames current dialogues around diagnostic accuracy, time-to-result, and decentralization, emphasizing how these factors shape adoption curves across public health programs and clinical pathways.
The narrative begins with a clear description of diagnostic modalities, followed by an exploration of demand-side drivers including testing guidelines, screening initiatives, and changing sexual health behaviors. It then transitions to the supply-side context, describing manufacturing capacity, regulatory alignment, and cross-border trade dynamics that influence product availability. The section closes by articulating the principal decision imperatives for stakeholders: optimizing diagnostic portfolios for sensitivity and scalability, designing service models that expand reach without compromising quality, and prioritizing investments that reduce time-to-diagnosis while maintaining cost-effectiveness.
How converging technological breakthroughs, regulatory evolution, and care-delivery redesign are reshaping diagnostic pathways and adoption dynamics across sexual health services
The diagnostics landscape is undergoing transformative shifts driven by scientific breakthroughs, regulatory evolution, and care-delivery redesign. Advances in nucleic acid amplification and next-generation sequencing have redefined sensitivity thresholds and enabled multiplexed pathogen detection, while CRISPR-based platforms and microfluidic lab-on-a-chip systems are opening pathways for high-performance decentralised testing. These technological shifts are complemented by the maturation of point-of-care formats, where rapid diagnostic tests and compact analyzers are increasingly viable for community screening and home-based testing models.
Concurrently, regulatory frameworks are adapting to balance expedited access with robust validation, leading to new pathways for emergency authorization and conditional approvals in certain jurisdictions. Health systems are also realigning around patient-centric care, prioritizing same-visit diagnosis and linkage to treatment to reduce transmission risk. The convergence of improved digital connectivity, telehealth, and remote sample collection is reshaping how tests are ordered, fulfilled, and integrated into care pathways, which in turn drives demand for interoperable data standards and secure reporting mechanisms. Taken together, these shifts create both opportunity and risk: innovators that align product performance with real-world workflow and reimbursement constraints will scale more rapidly, while fragmented approaches that ignore implementation realities will face adoption hurdles.
Assessing how recent tariff pressures are redirecting supply chains, elevating input costs, and prompting localization and partnership strategies across diagnostic value chains
The imposition and escalation of tariffs can materially affect the diagnostic ecosystem by altering input costs, redirecting supply chains, and influencing sourcing strategies. For manufacturers of instruments, consumables, and reagents, higher import tariffs increase landed costs for components such as reagent raw materials, plastics for consumables, and precision components used in analyzers. These cost pressures incentivize manufacturers to re-evaluate sourcing footprints, pursue near-shoring, or consolidate supplier relationships to preserve margins and maintain predictable supply.
From a distribution and end-user perspective, tariff-induced cost increases can cascade into higher per-test prices, influencing procurement decisions by hospitals, public health departments, and large laboratories. Buyers may respond by shifting volume to lower-cost suppliers, extending inventory horizons, or prioritizing multi-use instruments that reduce reliance on imported single-use consumables. Tariffs also accelerate strategic partnerships, contract manufacturing arrangements, and cross-border investment as firms seek to mitigate exposure to trade policy volatility. Finally, increased trade friction tends to heighten emphasis on regulatory harmonization and bilateral agreements that can restore market access and stabilize supply. In sum, tariffs in 2025 reshape commercial calculus, driving localization, supplier rationalization, and renewed focus on margin resilience without reducing the imperative for testing quality and timely access.
A nuanced segmentation framework connecting diagnostic modalities, pathogen biology, end-user settings, sampling protocols, technologies, and product forms to strategic decision-making
Insightful segmentation reveals how diagnostic strategies must be tailored to product capability, pathogen biology, end-user setting, sample modality, technology platform, and product form. Diagnostic test types span laboratory tests that include biomarker-based assays, blood tests, and urine tests; molecular tests that encompass next-generation sequencing, nucleic acid amplification tests, and polymerase chain reaction; and point-of-care tests that feature portable analyzers, rapid diagnostic tests, and self-test kits. Each test category presents distinct trade-offs between throughput, sensitivity, and decentralization, and clinical programs must align modality selection with screening intensity and linkage-to-care capacity.
Pathogen-focused segmentation highlights that bacterial STDs such as Chlamydia, Gonorrhea, and Syphilis require different diagnostic chemistries and sampling strategies compared with fungal infections like candidiasis, parasitic pathogens such as Trichomoniasis, or viral agents including Hepatitis B, Herpes Simplex Virus, HIV, and HPV. End-user segmentation underscores divergent operational realities: diagnostic laboratories, which include both pathology and research labs, operate at scale and favor high-throughput platforms; home care settings, encompassing direct-to-consumer testing and online pharmacies, prioritize ease-of-use and privacy; hospitals and clinics, from large healthcare facilities to outpatient clinics, require rapid, reliable results integrated into clinical workflows; and public health departments, including community health centers and state health departments, emphasize standardization, surveillance compatibility, and cost-effectiveness.
Sample-type distinctions-blood samples subdivided into plasma and serum, swab samples covering genital, oral, and rectal swabs, and urine samples differentiated by first-catch and midstream-drive collection protocols, patient instructions, and downstream assay validation. Technology-type segmentation highlights emergent platforms such as CRISPR-based diagnostics, immunoassays including ELISA and lateral flow formats, microfluidic lab-on-a-chip solutions, and spectroscopy approaches like infrared and Raman, each offering different performance envelopes and integration demands. Finally, product segmentation into consumables such as pipettes and tubes, instruments like analyzers and automation systems, and reagents and kits for bacterial and viral pathogens underscores commercial planning considerations: procurement cycles, recurring spend profiles, and opportunities for bundled service models. Integrating these segmentation axes enables more nuanced targeting, product development prioritization, and go-to-market strategies that reflect both clinical needs and operational realities.
How divergent regional priorities and infrastructure realities across the Americas, Europe, Middle East & Africa, and Asia-Pacific determine adoption pathways and commercialization strategies
Regional dynamics exert a powerful influence on diagnostic adoption and innovation pathways, and leaders should consider geographic differentiation when designing market entry and distribution plans. In the Americas, investment in public health infrastructure, expansive private laboratory networks, and progressive reimbursement policies support rapid uptake of molecular testing and decentralized point-of-care solutions, while persistent disparities in access and rural health delivery create targeted opportunities for portable and self-testing formats. Europe, Middle East & Africa presents a heterogeneous picture: Western Europe exhibits mature regulatory alignment and strong laboratory capacity that favor high-complexity assays, whereas parts of the Middle East and Africa face infrastructure limitations that elevate the importance of ruggedized rapid tests, simplified workflows, and capacity-building partnerships.
Asia-Pacific is characterized by rapid technological adoption, significant domestic manufacturing capabilities, and diverse market maturities; advanced economies in the region often drive early uptake of cutting-edge platforms such as CRISPR-based diagnostics and lab automation, while emerging markets prioritize affordability, supply chain resilience, and scalable point-of-care testing. Across all regions, cross-border regulatory pathways, local validation requirements, and procurement modalities such as centralized tenders or decentralized hospital purchasing shape commercialization timelines. Effective regional strategies therefore combine local regulatory intelligence, partnership models that address distribution and training needs, and product portfolios calibrated to the operational realities of each geography.
Competitive landscape analysis emphasizing platform modularity, strategic partnerships, and evidence-driven differentiation as determinants of commercial success in diagnostics
Competitive dynamics are driven by incumbents that command established channel relationships and newer entrants that leverage platform innovations to target unmet clinical needs. Leading instrument and reagent providers continue to invest in modular platforms that enable multiplex testing and automated workflows, while agile startups focus on disruptive point-of-care formats, CRISPR-based approaches, and integrated digital reporting. Strategic differentiation increasingly rests on system-level value propositions: ease of integration with laboratory information systems, demonstrable improvements in time-to-result linked to treatment initiation, and robust post-market performance data that supports payer and public-health adoption.
Partnerships between diagnostics companies and contract manufacturers or local distributors are accelerating market access, especially where regulatory landscapes require domestic representation or local validation. In addition, collaborations with digital health companies and telemedicine platforms are creating new pathways for test ordering, result delivery, and care navigation, broadening addressable use cases beyond traditional clinical settings. Firms that balance continuous product innovation with scalable manufacturing and clear evidence-generation plans will be best positioned to capture institutional procurement and public health contracts, while those that over-index on novelty without clear implementation strategies risk slow adoption.
Practical and prioritized recommendations for executives to align innovation, supply resilience, evidence generation, and partnerships that accelerate adoption
Industry leaders should prioritize a set of pragmatic actions that balance innovation with implementation to accelerate impact and commercial traction. First, align product development with validated clinical workflows by engaging early with healthcare providers and public-health stakeholders to ensure assays address real-world sample types, throughput needs, and reporting requirements. Second, build resilient supply chains through supplier diversification, regional manufacturing partnerships, and inventory strategies that mitigate tariff and trade volatility while protecting quality standards.
Third, invest in evidence generation that demonstrates improved patient outcomes, linkage to care, and cost-effectiveness under routine conditions, thus facilitating payer engagement and public-health procurement. Fourth, pursue strategic commercial partnerships for distribution, training, and after-sales support to reduce barriers to adoption in resource-limited settings. Fifth, design digital interoperability into products from the outset to enable seamless data exchange with electronic health records and surveillance systems. Taken together, these recommendations create a pragmatic roadmap that balances near-term access goals with longer-term innovation and scale.
A transparent research methodology integrating primary stakeholder interviews, secondary literature synthesis, and rigorous validation to ensure practical and actionable insights
The research methodology combines structured primary outreach, rigorous secondary-source synthesis, and cross-validation of technical performance claims to ensure analytical robustness. Primary inputs included structured interviews with clinical laboratory directors, public-health officials, procurement officers, and R&D leaders, along with anonymized input from device engineers and assay developers to capture implementation constraints and performance expectations. Secondary research synthesized peer-reviewed literature, regulatory guidance documents, technology validation studies, and public health surveillance reports to contextualize clinical needs and technological capabilities.
Analytical methods used a matrixed approach to map technology attributes against clinical and operational requirements, and included scenario analysis to consider supply-chain disruptions and policy shifts. Validation steps included triangulation across multiple stakeholder types and review of real-world implementation case studies to ensure the findings reflect practical constraints. Where appropriate, technical claims and performance metrics were reviewed against published validation studies and regulatory summaries to maintain factual accuracy and applicability for decision-making audiences.
A definitive synthesis that links technological innovation, implementation realities, and strategic imperatives to drive measurable impact across diagnostic and public health objectives
In conclusion, the diagnostics sector for sexually transmitted infections is at an inflection point where scientific advances, evolving care models, and shifting trade dynamics converge to redefine how testing is delivered and scaled. The most successful strategies will integrate high-performance assays with pragmatic deployment plans that reflect the realities of sample collection, laboratory capacity, and payer expectations. Continued innovation will be necessary to close persistent gaps in access, particularly for underserved populations and decentralized settings where point-of-care and self-test modalities can have outsized impact.
Stakeholders must prioritize evidence generation that links diagnostic performance to patient outcomes, invest in resilient supply chains and regional partnerships to mitigate policy-driven risk, and design products with interoperability and usability at their core. By combining technological rigor with implementation-focused commercialization, organizations can translate diagnostic innovation into measurable public-health benefit and sustainable commercial value.
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
187 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Integration of rapid point-of-care molecular assays in community health settings to reduce time to diagnosis
- 5.2. Development of multiplexed testing platforms for simultaneous detection of multiple STDs including emerging pathogens
- 5.3. Adoption of self-collection and at-home sampling kits for decentralized STD screening in high-risk populations
- 5.4. Implementation of AI-driven data analytics for predictive modeling of STD outbreaks and personalized treatment strategies
- 5.5. Increasing use of CRISPR-based diagnostics for highly sensitive and specific detection of chlamydia and gonorrhea
- 5.6. Collaboration between telemedicine providers and diagnostic manufacturers to expand remote STD testing access
- 5.7. Focus on antibiotic resistance detection assays to guide targeted therapy for drug-resistant gonorrhea infections
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Sexually Transmitted Disease Diagnostics Market, by Product Types
- 8.1. Consumables
- 8.1.1. Pipettes
- 8.1.2. Tubes
- 8.2. Instruments
- 8.2.1. Analyzers
- 8.2.2. Automation Systems
- 8.3. Reagents and Kits
- 8.3.1. Kits for Bacterial STDs
- 8.3.2. Kits for Viral STDs
- 9. Sexually Transmitted Disease Diagnostics Market, by Diagnostic Test Types
- 9.1. Laboratory Tests
- 9.1.1. Biomarker-Based Tests
- 9.1.2. Blood Tests
- 9.1.3. Urine Tests
- 9.2. Molecular Tests
- 9.2.1. Next-Generation Sequencing
- 9.2.2. Nucleic Acid Amplification Tests (NAATs)
- 9.2.3. Polymerase Chain Reaction (PCR)
- 9.3. Point-of-Care Tests
- 9.3.1. Portable Analyzers
- 9.3.2. Rapid Diagnostic Tests
- 9.3.3. Self-Test Kits
- 10. Sexually Transmitted Disease Diagnostics Market, by Pathogen Types
- 10.1. Bacterial STDs
- 10.1.1. Chlamydia
- 10.1.2. Gonorrhea
- 10.1.3. Syphilis
- 10.2. Fungal STDs
- 10.3. Parasitic STDs
- 10.4. Viral STDs
- 10.4.1. Hepatitis B
- 10.4.2. Herpes Simplex Virus
- 10.4.3. Human Immunodeficiency Virus (HIV)
- 10.4.4. Human Papillomavirus (HPV)
- 11. Sexually Transmitted Disease Diagnostics Market, by Sample Types
- 11.1. Blood Samples
- 11.1.1. Plasma
- 11.1.2. Serum
- 11.2. Swab Samples
- 11.2.1. Genital Swabs
- 11.2.2. Oral Swabs
- 11.2.3. Rectal Swabs
- 11.3. Urine Samples
- 11.3.1. First Catch
- 11.3.2. Midstream
- 12. Sexually Transmitted Disease Diagnostics Market, by Technology Types
- 12.1. CRISPR-Based Diagnostics
- 12.2. Immunoassays
- 12.2.1. ELISA
- 12.2.2. Lateral Flow Assays
- 12.3. Microfluidics
- 12.4. Spectroscopy
- 12.4.1. Infrared
- 12.4.2. Raman Spectroscopy
- 13. Sexually Transmitted Disease Diagnostics Market, by End-User Types
- 13.1. Diagnostic Laboratories
- 13.1.1. Pathology Laboratories
- 13.1.2. Research Laboratories
- 13.2. Home Care Settings
- 13.2.1. Direct-to-Consumer Testing
- 13.2.2. Online Pharmacies
- 13.3. Hospitals and Clinics
- 13.3.1. Healthcare Facilities
- 13.3.2. Outpatient Clinics
- 13.4. Public Health Departments
- 13.4.1. Community Health Centers
- 13.4.2. State Health Departments
- 14. Sexually Transmitted Disease Diagnostics Market, by Region
- 14.1. Americas
- 14.1.1. North America
- 14.1.2. Latin America
- 14.2. Europe, Middle East & Africa
- 14.2.1. Europe
- 14.2.2. Middle East
- 14.2.3. Africa
- 14.3. Asia-Pacific
- 15. Sexually Transmitted Disease Diagnostics Market, by Group
- 15.1. ASEAN
- 15.2. GCC
- 15.3. European Union
- 15.4. BRICS
- 15.5. G7
- 15.6. NATO
- 16. Sexually Transmitted Disease Diagnostics Market, by Country
- 16.1. United States
- 16.2. Canada
- 16.3. Mexico
- 16.4. Brazil
- 16.5. United Kingdom
- 16.6. Germany
- 16.7. France
- 16.8. Russia
- 16.9. Italy
- 16.10. Spain
- 16.11. China
- 16.12. India
- 16.13. Japan
- 16.14. Australia
- 16.15. South Korea
- 17. Competitive Landscape
- 17.1. Market Share Analysis, 2024
- 17.2. FPNV Positioning Matrix, 2024
- 17.3. Competitive Analysis
- 17.3.1. Abbott Laboratories
- 17.3.2. Astra Biotech Gmbh
- 17.3.3. Becton Dickinson and company
- 17.3.4. Bio-Rad Laboratories, Inc.
- 17.3.5. bioMérieux SA
- 17.3.6. Danaher Corporation
- 17.3.7. Daye Limited
- 17.3.8. Diasorin S.p.A
- 17.3.9. F. Hoffmann-La Roche Ltd
- 17.3.10. Geneproof
- 17.3.11. Hologic Inc.
- 17.3.12. Jiangsu BioPerfectus Technologies Co., Ltd
- 17.3.13. Liferiver Bio-Tech Corp.
- 17.3.14. MedMira Inc
- 17.3.15. Meridian Bioscience Inc.
- 17.3.16. Mylab Discovery Solutions Pvt. Ltd.
- 17.3.17. OraSure Technologies, Inc.
- 17.3.18. Qiagen Inc
- 17.3.19. Quest Consumer Inc.
- 17.3.20. Sansure Biotech Inc.
- 17.3.21. Seegene Inc.
- 17.3.22. Siemens Healthcare GmbH
- 17.3.23. Thermo Fisher Scientific, Inc.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
